EGFR and non-small cell lung carcinoma: Multiple studies have shown that targeted therapy, represented by EGFR tyrosine kinase inhibitors (EGFR-TKIs), not only significantly prolongs the progression free survival (PFS) of patients with advanced NSCLC, but also improves their quality of life, which has revolutionized the treatment of patients with advanced NSCLC.